|
David R. Stevens Ph.D. has been a director since May 2004. He has worked in the pharmaceutical and biotechnology industries since 1978. He is currently executive chairman and a member of the Board of Directors of Surginetics Inc. a development stage medical device company. Dr. Stevens is also chairman of CanCog Technologies Inc. a contract research organization and a director of Advance Cosmetic Intervention Inc. a medical device company and Aqua Bounty Technologies Inc. a biotechnology firm. He has been an advisor to Bay City Capital LLC from 1999 to 2006. Dr. Stevens was formerly president and CEO of Deprenyl Animal Health Inc. from 1990 to 1998 and vice president research and development of Agrion Corp from 1985 to 1988. He began his career in pharmaceutical research and development at the former Upjohn Company where he contributed to the preclinical development of Xanax® and Halcion®. Dr. Stevens received B.S. and D.V.M. degrees from Washington State University and a Ph.D. in Comparative Pathology from the University of California Davis. He is a diplomate of the American College of Veterinary Pathologists. | 